North America Gastric Cancer Diagnostic Procedure Market is expected to reach US$ 758.16 million by 2028

Publisher: The Insight Partners

Imaging Tests Segment to Hold Largest Share of North America Gastric Cancer Diagnostic Procedure Market During 2022–2028

According to our latest study on “North America Gastric Cancer Diagnostic Procedures Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Healthcare Providers, Symptom Types, Body Fluids, Procedures, Offerings, and Disease Indication,” the market is expected to grow from US$ 567.26 million in 2022 to US$ 758.16 million by 2028; it is estimated to record a CAGR of 4.9% from 2022 to 2028. The report highlights the key factors driving the market and prominent players with their developments in the market.  

Gastric cancer is a type of malignant cancer that forms the stomach's inner lining. Risk factors such as age, unhealthy diet, and stomach diseases can lead to the development of gastric cancer. Symptoms of gastric cancer include indigestion, heartburn, bloating, and stomach discomfort or pain. The presence of a huge patient population affected by gastrointestinal tumors, lymphoma, and adenocarcinoma, the increase in the geriatric population, and the rise in consumption of alcohol and smoking are among the factors contributing to the growth of the North America gastric cancer diagnostic procedure market.

Development of AI-Based Gastric Cancer Diagnostic Platform to Drive Market Growth in Coming Years

Many market players and research institutes operating in the gastric cancer diagnostics procedures market are developing advanced products to expand their product portfolios and increase their market shares. They invest significant amounts in R&D to develop advanced products. A few of the recent developments related to gastric cancer diagnostic platforms are mentioned below:

Ibex Medical Analytics, a pioneer in AI-powered cancer diagnostics, developed the world’s first artificial intelligence (AI) platform to detect cancer. Its AI algorithms analyze images of biopsies and can pinpoint their location and grade the tumor. These results help pathologists diagnose gastric cancer accurately. In June 2021, the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to Ibex’s Galen platform, which will expedite the clinical review and regulatory approval of its platform. Galen Gastric is an integrated diagnostics and quality control solution that supports pathologists in the detection of gastric cancer, dysplasia, H. pylori, and other important clinical findings. 

• In November 2019, AI Medical Service Inc., one of the world's first real-time endoscopic AI developers, secured Breakthrough Device Designation by the US FDA for its AI programs that analyze endoscopy images for potential diagnosis of gastric cancer.
• In February 2022, Mayo Clinic researchers used AI and informatics to discover a 32-gene signature that is a prognostic and predictive biomarker for patients suffering from gastric cancer. The study was published in the edition of Nature Communications.

Thus, such development of AI-based gastric cancer diagnostics is likely to introduce new trends in the North America gastric cancer diagnostic procedure market during the forecast period.

The North America gastric cancer diagnostic procedure market, based on procedures, is segmented into endoscopic procedures, biopsy & tissue tests, lab tests, in-vitro diagnostic tests, imaging tests, molecular diagnostics, multiplexing molecular diagnostics & immunoassays, and others. In 2021, the imaging tests segment held the largest share of the market. The biopsy and tissue tests segment is expected to record the highest growth rate in the coming years. Imaging tests are used to diagnose and stage stomach cancer. They include computed tomography (CT) scans, magnetic resonance imaging (MRI), positron emission tomography/computed tomography (PET/CT) scans, ultrasound, and others. CT scans provide detailed images of the abdomen, and the images help doctors detect cancer and find its location in the stomach and see its transmission to other abdominal organs. MRI utilizes strong magnetic fields and radio waves to create detailed images of the location and allow a greater soft tissue contrast compared to a CT scan. MRI is not used as frequently as a CT scan to detect stomach cancer, but it is useful to determine the spread of cancer to other organs, such as the liver. PET/CT scans allow doctors to detect stomach cancer and determine its stage as well as its growth.

Further, ultrasound can be preferred if fluid is found in the abdomen. Ultrasound produces images of organs from high-energy sound waves and echoes to help detect and stage stomach cancer. It may also be used to check tumors spread to other organs. The upper gastrointestinal series is a series of highlighted X-rays of the stomach, esophagus, and the upper portion of the small intestine. This procedure requires the patient to swallow barium, which enhances the X-ray images. If doctor finds abnormalities during this procedure, the next step may be an endoscopic procedure or another diagnostic imaging test. These tests help in detecting and staging stomach cancer. Some other tests include laparoscopy. Doctors might do a laparoscopy before any other surgery. This can help confirm the cancer is still only in the stomach, which means surgery to remove it might still be an option. Sometimes laparoscopy is combined with Ultrasound to give a better picture of cancer.

Atlas-Link Biotech Co Ltd, Bio-Rad Laboratories Inc, MiRXES Pte Ltd, Agilent Technologies Inc, F. Hoffmann-La Roche Ltd, bioMerieux SA, Thermo Fisher Scientific Inc, Illumina Inc, Vela Diagnostics Holding Pte Ltd, and Myraid Genetics Inc. are among the leading companies operating in the North America gastric cancer diagnostic procedure market.

The report segments the North America gastric cancer diagnostic procedure market as follows 

The North America gastric cancer diagnostic procedure market, based on healthcare providers, is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others. The North America gastric cancer diagnostic procedure market, by symptom types, is bifurcated into symptomatic and asymptomatic. The market, by body fluid, is segmented into blood, urine, saliva, stomach wash/gastric juice, tissue, and others. The North America gastric cancer diagnostic procedure market, based on procedures, is segmented into endoscopic procedures, biopsy and tissue tests, lab tests, in-vitro diagnostic tests, imaging tests, molecular diagnostics, multiplexing molecular diagnostics and immunoassays, and others. The market, based on offerings, is segmented into instruments, reagents and consumables, and services. The North America gastric cancer diagnostic procedure market, based on disease indication, is segmented into early gastric cancer and advanced gastric cancer.

Contact Us
Contact Person: Content Team 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com